中山肛裂需要手术吗中山华都肛肠医院胃镜,中山看脱肛医院,中山痔疮做微创手术多少钱,中山外痔最好医院,中山大便出血但是不疼,中山哺乳期痔疮犯了怎么办,中山屁眼流血了一般是什么事

The Supreme Court on Tuesday invalidated a provision of federal law that requires the mandatory deportation of immigrants who have been convicted of some crimes, holding that the law is unconstitutionally vague.The case, Sessions v. Dimaya, had been closely watched to see if the justices would reveal how they will consider the Trump administration's overall push to both limit immigration and increase deportations.As expected after the oral argument, Justice Neil Gorsuch joined with the more liberal justices for the first time since joining the court to produce a 5-4 majority invalidating the federal statute. In doing so, Gorsuch was continuing the jurisprudence of Justice Antonin Scalia, who also sided with liberals when it came to the vagueness of statutes used to convict criminal defendants.Only eight justices heard the case last term after Scalia's death, and in late June, the court announced it would re-hear arguments this term, presumably so that Gorsuch could break some kind of a tie.Dimaya, a native of the Philippines, was admitted to the United States in 1992 as a lawful permanent resident. In 2007 and 2009, he pleaded no contest to charges of residential burglary in California and an immigration judge determined that Dimaya was removable from the US because of his two state court convictions.The court held that the convictions qualified for an "aggravated felony" under the Immigration and Nationality Act, which authorizes removal of non-citizens who have been convicted of some violent crimes and defines aggravated felony to include "crimes of violence."Lawyers for Dimaya appealed the removal arguing that it was unconstitutionally vague and that their client never had fair notice that his crimes would result in deportation.They suggested the reasoning of a 2015 Scalia opinion, which struck a provision of the Armed Career Criminal Act as unconstitutionally vague, should extend to their case.  1945

The Trump administration has reportedly reversed a decision made earlier in the day to deny sending relief to California for several wildfires that have scorched the state. Wildfires in California have burned a record-breaking 4 million acres in 2020, with many still burning. In a tweet Friday afternoon, California Governor Gavin Newsom said “Just got off phone with @realDonaldTrump who has approved our Major Disaster Declaration request.” 451

The World Health Organization updated its guidelines on mask-wearing Tuesday, recommending that anyone over the age of 12 wear a mask indoor and outdoor and inside your home if it's ventilated poorly.The updated guidelines come as COVID-19 cases continue to sore in America. On Wednesday, 180,083 new cases were reported, according to data from Johns Hopkins University.According to the guidelines, in areas where COVID is spreading, WHO recommends that anyone over the age of 12 wear masks in shops, shared workplaces, and schools if they can't maintain a distance of more than 3-feet between others.They also recommend masks be worn when people visit your home if there's not adequate ventilation, or you can't be more than 3-feet or more from each other.The WHO said on top of wearing a mask, other precautions such as washing hands, avoiding touching your face, having adequate ventilation if indoors, testing, contact tracing, quarantine, and isolation should also be taken."Together, these measures are critical to prevent human-to-human transmission of COVID-19," WHO said.In areas of COVID-19 spread, the organization said healthcare workers should take part in "universal masking" in health care facilities, meaning they should wear an N95 respirator mask throughout their entire shift, including when caring for other patients.The advice applied to visitors, outpatients, and common areas such as cafeterias and staff rooms, but added administrative staff does not need to wear a mask if they are not exposed to patients.The organization also recommended that people who do vigorous physical activity should not wear masks, citing some associated risks, particularly asthma.For children, the WHO recommends children up to 5-years-old should not wear masks for source control. They added that children between the ages of 6 to 11-years-old should only wear masks if "a risk-based approach is applied.""Factors to be considered in the risk-based approach include intensity of COVID-19 transmission, child’s capacity to comply with the appropriate use of masks and availability of appropriate adult supervision, local social and cultural environment, and specific settings such as households with elderly relatives, or schools," the organization added in its guidelines. 2285

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

The Sanderson Sisters are hoping to put a spell on you, 27 years later.Actress Bette Midler was recently on Fox 5 New York's morning show "Good Day New York" where she confirmed that the original cast of "Hocus Pocus" was reuniting for a sequel.“They want to make a movie, they’ve asked us if we were interested and of course all of us said yes,” Midler said in the interview. “I’m game, I’m totally game.”The movie won’t be the first time the Sanderson Sisters would be reuniting. Midler, Sarah Jessica Parker, and Kathy Najimy are coming together, as their “Hocus Pocus” characters, for a special live, one-night-only virtual event, “In Search Of The Sanderson Sisters,” which is set for Friday. 705